Reed Research
Biotech, small-cap, long/short equity, special situations

Exact Sciences Is A Near-Term Short Due To Risks And Assumptions About Its Future Business

The market need for Cologuard

Only 0.3% of the population currently suffers from colon cancer, but the lifetime risk is higher at 5%, which benefits the colon cancer screening market. According to the American Cancer Society: "96,830 new cases of colon cancer and 40,000 new cases of rectal cancer are expected in 2014. Colorectal cancer is expected to cause about 50,310 deaths during 2014." Here are the cancer survival rates by stage and we can see that there is a clear market need for accurate early detection of colorectal cancers.

The death rate from colorectal cancer has decreased in both men and women in the past two decades most likely due to a higher likelihood of polyps being found...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details